H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of ...

Leiden, the Netherlands Saturday, March 22, 2025, 12:00 Hrs [IST] ...

Q4 2024 Management View CEO Fabrice Chouraqui highlighted a strong performance in 2024 with revenue growth of 21% to $297 million, exceeding guidance. He emphasized RUCONEST's growth of 11% to $252 ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

Pharming Group (NASDAQ:PHAR – Get Free Report) had its price target hoisted by research analysts at Oppenheimer from $30.00 ...

Phishing is quite a broad term, therefore organisations and individuals could benefit from breaking down the phrase and ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...

The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...

Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).

(RTTNews) - Pharming Group (PHARM), on Thursday, announced that the first patient has been dosed in its Phase II clinical trial of Leniolisib for the treatment of Common Variable Immunodeficiency ...